{"id":"W4385857188","doi":"10.1016/j.eururo.2023.08.004","title":"Phase 2 Trial of Atezolizumab in Bacillus Calmette-Guérin–unresponsive High-risk Non–muscle-invasive Bladder Cancer: SWOG S1605","year":2023,"lang":"en","type":"article","venue":"European Urology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":91,"is_retracted":false,"has_abstract":false,"ca_institutions":"McGill University Health Centre; University of British Columbia; University of British Columbia Hospital","funders":"National Cancer Institute, Cairo University; AstraZeneca; Genentech; American College of Radiology Imaging Network; Astellas Pharma; National Cancer Institute; National Institutes of Health","keywords":"Medicine; Atezolizumab; Bladder cancer; Oncology; Internal medicine; Bacillus (shape); Urology; Cancer; Immunotherapy; Pembrolizumab","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0005001667,0.0003513489,0.0007784855,0.0005070617,0.00007931838,0.000009584241,0.0002413179,0.0001353014,0.0006039186],"category_scores_gemma":[0.0004997294,0.0003111062,0.0002053744,0.0007375236,0.0002327008,0.00006245306,0.0001620818,0.0004602847,0.0008044676],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001216874,"about_ca_system_score_gemma":0.0004086617,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00146756,"about_ca_topic_score_gemma":0.0003887175,"domain_scores_codex":[0.9968643,0.0008347789,0.000675819,0.0006592729,0.0003212052,0.0006446792],"domain_scores_gemma":[0.9983354,0.0004205501,0.0002709161,0.0006136943,0.0001393968,0.000220061],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.4595217,0.008179943,0.01953638,0.0003754104,0.003664221,0.02615501,0.01135827,0.00128031,0.03529895,0.0003403362,0.0506403,0.3836492],"study_design_scores_gemma":[0.6636736,0.04140805,0.2309044,0.0001368106,0.001662671,0.0001364049,0.0004390715,0.0003140981,0.008756852,0.0002888677,0.05138109,0.0008980625],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9878404,0.0003649493,0.00002659506,0.001584331,0.001118832,0.00112809,0.0003591996,0.0001343188,0.00744333],"genre_scores_gemma":[0.9949433,0.001289594,0.00004757533,0.001140887,0.0007308329,0.00009702833,0.0001125401,0.0001087773,0.001529466],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.3827511,"threshold_uncertainty_score":0.9999735,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02481132804888801,"score_gpt":0.3123821855103267,"score_spread":0.2875708574614387,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}